The Penicillins and Streptomycins in Dosage market in China showed a value per capita of $0.54 in 2023. Forecasts for 2024 to 2027 indicate a steady value of $0.55, with a slight increase to $0.56 by 2028, reflecting minimal growth. This marks less than a 2% cumulative increase from 2023 to 2028, translating to a negligible year-on-year growth and stable market trends over this period. The compound annual growth rate (CAGR) over these years is therefore estimated to remain very modest.

Future trends to watch for include:

Potential impacts of emerging healthcare policies in China aimed at reducing antibiotic usage, which could affect market dynamics.
The growth of alternative treatments and innovations in pharmaceuticals that may shift consumer behavior.
Global supply chain factors that could influence pricing and availability of raw materials for these antibiotics.